Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia

Affiliations

• ¹ School of Medicine, University of Western Australia and Department of Cardiology, Royal Perth Hospital, Perth, Australia.
• ² Robarts Research Institute, London, Ontario, Canada.
• ³ Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mt Sinai, Mount Sinai, New York, NY.
• ⁴ NYU School of Medicine, NYU Langone Health, New York City, NY.
• ⁵ Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Pitie-Salpetriere Hospital, AP-HP, Paris, France.
• ⁶ Department of Endocrinology, University Hospitals Leuven - KU Leuven, Leuven, Belgium.
• ⁷ Department of Medicine, McGill University and Genetic Dyslipidemia Clinic, Montréal Clinical Research Institute (IRCM), Montréal, Québec, Canada.
• ⁸ Arrowhead Pharmaceuticals, Pasadena, CA.
• ⁹ Arrowhead Pharmaceuticals, UNITED STATES.
• ¹⁰ Université de Montréal and ECOGENE 21, Montréal, Québec, Canada.
• ¹¹ Stanford University, Palo Alto, CA.